{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:35:04Z","timestamp":1777498504885,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Evid Based Complementary Altern Med"],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Our previous articles showed that suppressive or preventive treatment with the herbal Gene-Eden-VIR\/Novirin reduced the number and duration of genital herpes outbreaks with no adverse effects. These studies also revealed that the herbal Gene-Eden-VIR\/Novirin is mostly superior to acyclovir, valacyclovir, and famciclovir drugs in genital herpes. This study tested the effect of Gene-Eden-VIR\/Novirin in oral herpes (also called cold sores and fever blisters).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>The framework of the study was a retrospective chart review. The study included 68 participants. The participants took 1 to 4 capsules per day over a period of 2 to 36 months. The study included 2 Food and Drug Administration\u2013recommended controls: baseline and a no-treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Gene-Eden-VIR\/Novirin was effective in 89.3% of participants. The treatment reduced the mean number of outbreaks per year from 6.0 and 3.6 in the control groups to 2.0 in the treatment group ( P &lt; .0001 and P = .07, respectively). Gene-Eden-VIR\/Novirin reduced the mean duration of outbreaks from 9.8 and 5.8 days in the control groups to 3.2 days in the treatment group ( P &lt; .0001 and P = .02, respectively). There were no reports of adverse experiences. Gene-Eden-VIR\/Novirin was compared to acyclovir and valacyclovir in 6 tests. In all tests, Gene-Eden-VIR\/Novirin showed higher efficacy. Gene-Eden-VIR\/Novirin also showed superior safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>This clinical study showed that suppressive or preventive treatment with the herbal Gene-Eden-VIR\/Novirin reduced the number and duration of outbreaks in oral herpes without any adverse effects. The study also showed that the herbal Gene-Eden-VIR\/Novirin had better clinical effects than acyclovir and valacyclovir, the leading drugs in the category. Based on these results, we recommend using the herbal Gene-Eden-VIR\/Novirin as preventive treatment for oral herpes and, specifically, as an alternative to the acyclovir and valacyclovir drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2515690x18806269","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T06:42:57Z","timestamp":1540536177000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Trial of Herbal Treatment Gene-Eden-VIR\/Novirin in Oral Herpes"],"prefix":"10.1177","volume":"23","author":[{"given":"Hanan","family":"Polansky","sequence":"first","affiliation":[{"name":"The Center for the Biology of Chronic Disease, Valley Cottage, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Javaherian","sequence":"additional","affiliation":[{"name":"The Center for the Biology of Chronic Disease, Valley Cottage, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edan","family":"Itzkovitz","sequence":"additional","affiliation":[{"name":"The Center for the Biology of Chronic Disease, Valley Cottage, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,10,26]]},"reference":[{"issue":"8","key":"bibr1-2515690X18806269","first-page":"CD010095","author":"Chi CC","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr2-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197707142970201"},{"key":"bibr3-2515690X18806269","first-page":"239","volume":"71","author":"Baker D","year":"2003","journal-title":"Cutis"},{"key":"bibr4-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02150-13"},{"key":"bibr5-2515690X18806269","first-page":"510","volume":"51","author":"Sciubba JJ","year":"2003","journal-title":"Gen Dent"},{"key":"bibr6-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209103271108"},{"key":"bibr7-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297914130124"},{"key":"bibr8-2515690X18806269","first-page":"400","volume":"6","author":"Gilbert SC","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"bibr9-2515690X18806269","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0002-9343(88)90375-0","volume":"85","author":"Mattison HR","year":"1988","journal-title":"Am J Med"},{"key":"bibr10-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.2.185"},{"key":"bibr11-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.02.031"},{"key":"bibr12-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1072-1080.2003"},{"key":"bibr13-2515690X18806269","first-page":"95","volume":"44","year":"2002","journal-title":"Med Lett Drugs Ther"},{"key":"bibr14-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035144"},{"key":"bibr15-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7022.6"},{"key":"bibr16-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-4-199302150-00004"},{"key":"bibr17-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00369"},{"key":"bibr18-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2015.00066"},{"key":"bibr19-2515690X18806269","volume-title":"Microcompetition With Foreign DNA and the Origin of Chronic Disease","author":"Polansky H","year":"2003"},{"key":"bibr20-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.4236\/pp.2013.46A001"},{"key":"bibr21-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S112852"},{"key":"bibr22-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-016-0121-6"},{"key":"bibr23-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.4236\/pp.2014.53035"},{"key":"bibr24-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00601.x"},{"key":"bibr25-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.3352\/jeehp.2013.10.12"},{"key":"bibr26-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.12968\/bjcn.2011.16.2.90"},{"key":"bibr27-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-10-153"},{"key":"bibr28-2515690X18806269","unstructured":"US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Guidance for industry. E 10 choice of control group and related issues in clinical trials. https:\/\/permanent.access.gpo.gov\/LPS113943\/LPS113943\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/ucm129460.pdf. Published May 2001. Accessed September 25, 2018."},{"key":"bibr29-2515690X18806269","first-page":"611","volume":"37","author":"Yavuz BB","year":"2005","journal-title":"Scand J Infect Dis"},{"key":"bibr30-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80939-5"},{"key":"bibr31-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.09.001"},{"issue":"8","key":"bibr32-2515690X18806269","first-page":"CD009036","author":"Le Cleach L","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr33-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.12.008"},{"key":"bibr34-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0528.2001.00005.x"},{"key":"bibr35-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90132-5"},{"key":"bibr36-2515690X18806269","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31821d4ceb"},{"key":"bibr37-2515690X18806269","first-page":"92","volume":"3","author":"Agambire R","year":"2014","journal-title":"J Biol Agric Healthcare"}],"container-title":["Journal of Evidence-Based Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515690X18806269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2515690X18806269","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515690X18806269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:09:45Z","timestamp":1777388985000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2515690X18806269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":37,"alternative-id":["10.1177\/2515690X18806269"],"URL":"https:\/\/doi.org\/10.1177\/2515690x18806269","relation":{},"ISSN":["2515-690X","2515-690X"],"issn-type":[{"value":"2515-690X","type":"print"},{"value":"2515-690X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"article-number":"2515690X18806269"}}